Why the study?
Does low-molecular-weight heparin reduce platelet activation compared to unfractionated heparin in healthy volunteers?
Does low-molecular-weight heparin reduce platelet activation compared to unfractionated heparin in healthy volunteers?
Low-molecular-weight heparin exhibits reduced platelet activating activity compared to unfractionated heparin, with the effect disappearing below 3,000 daltons.
Answers are grounded in this paper and cite their sources.
May inform heparin selection to limit platelet activation; leaves open clinical outcome impact in patients.
Heparin-induced alterations of platelet function have repeatedly been reported over the last 30 years. The development of low-molecular-weight (LMW) heparin fractions prompted us to compare the effect of unfractionated (UF) heparin and LMW heparin on platelet function. Heparin was applied intravenously to healthy volunteers in a dose of 100 U (antifactor Xa)/kg body weight. Sequential evaluation of platelet function ex vivo confirmed that UF heparin may activate platelets in vivo. Studying the ADP-induced fibrinogen binding to platelets in vivo, we were able to show that the effect of heparin on platelets is antibody- and antithrombin-III-independent. LMW heparin fractions in general exhibit a reduced platelet activating activity although there are differences between the LMW heparin fractions available. The stimulating effect of LMW heparin on platelets disappears below a mean molecular weight of 3,000 daltons.
No takes yet. Share an insight, caveat, or question.
Heinrich et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: